Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Innate Pharma S.A. IPHA

Set alert

Price alert · IPHA

All alert types
1.40 USD -0.06 -4.11%

At close · Nov 2

1.39 -0.01 -0.71%

After hours · Nov 2, 4:00 PM ET

Bid
1.39 × 1
Ask
1.41 × 1
1.38 Day range 1.44
1.17 52-week range 2.71
YTD
-20.00%
1 year
-28.93%
Open
1.44
Prev close
1.46
Mkt cap
156.38M
Vol
32.77K
Avg vol
159.36K
EPS
-0.62
P/E
0.00
Div yield
0.00%
More statistics
Low
1.38
High
1.44
Forward P/E
4.67
Beta
0.87
Short ratio
5.63
Inst. own
0.50%
Dividend
0.00
Ex-div date
Earnings
Mar 21, 2024
50-d avg
1.82
200-d avg
2.23
1y target
7.41

1Y chart

Chart tools
Interval
1m5m15m30m

Signals (60)
NameDateAgo
MACD: Buy SignalOct 20, 20261 week ago
RSI: OversoldOct 7, 20263 weeks ago
SMA: BearishSep 24, 20261 month ago
SMA: BearishSep 17, 20261 month ago
SMA: BullishSep 16, 20261 month ago
SMA: BearishSep 9, 20261 month ago
MACD: Sell SignalAug 27, 20262 months ago
RSI: OverboughtAug 12, 20262 months ago
SMA: BullishAug 10, 20262 months ago
MACD: Buy SignalAug 10, 20262 months ago
RSI: OverboughtAug 10, 20262 months ago
MACD: Sell SignalAug 7, 20262 months ago
MACD: Buy SignalAug 6, 20262 months ago
SMA: BullishAug 4, 20263 months ago
SMA: BearishAug 3, 20263 months ago
SMA: BearishJul 30, 20263 months ago
SMA: BullishJul 29, 20263 months ago
SMA: BullishJul 29, 20263 months ago
SMA: BearishJul 28, 20263 months ago
SMA: BullishJul 21, 20263 months ago

Newest 20 of 60.

Analyst view

Consensus: buy

Buy
Price target (mean) 7.41 +429.4% upside
Target (low)
2.56
Target (mean)
7.41
Target (high)
11.50
Ratings (0m) 5 4 buy · 1 hold · 0 sell
  • Strong buy1
  • Buy3
  • Hold1
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 5
  • 1 month ago 5
  • 2 months ago 5
  • 3 months ago 5

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

IPHA analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter0.000.00 – 0.000.000.0%00.0%0
Next quarter0.000.00 – 0.000.000.0%00.0%0
Current year0.000.00 – 0.000.000.0%53.68M-12.9%0
Next year0.000.00 – 0.000.000.0%85.66M+59.6%0

Upgrades and downgrades

The latest rating changes

IPHA analyst upgrades and downgrades
DateFirmActionFromTo
Dec 9, 2024HC Wainwright & Co.ReiteratedBuyBuy
Nov 15, 2024HC Wainwright & Co.ReiteratedBuyBuy
Nov 12, 2024HC Wainwright & Co.ReiteratedBuyBuy
Sep 13, 2024HC Wainwright & Co.ReiteratedBuyBuy
Jun 12, 2024HC Wainwright & Co.ReiteratedBuyBuy
May 15, 2024HC Wainwright & Co.ReiteratedBuyBuy
Apr 11, 2024HC Wainwright & Co.ReiteratedBuyBuy
Mar 22, 2024HC Wainwright & Co.ReiteratedBuyBuy
Nov 15, 2023HC Wainwright & Co.ReiteratedBuyBuy
Sep 18, 2023HC Wainwright & Co.ReiteratedBuyBuy
Jun 16, 2023HC Wainwright & Co.ReiteratedBuyBuy
Mar 24, 2023HC Wainwright & Co.Reiterated—Buy
Nov 15, 2022SVB LeerinkMaintained—Outperform
Sep 16, 2022CitigroupMaintained—Buy
Aug 2, 2022SVB LeerinkMaintained—Outperform
May 11, 2022SVB LeerinkMaintained—Outperform
Sep 17, 2021SVB LeerinkMaintained—Outperform
Sep 3, 2021SVB LeerinkUpgradeMarket PerformOutperform
Sep 2, 2021SVB LeerinkUpgradeMarket PerformOutperform
Mar 19, 2021SVB LeerinkMaintained—Market Perform
Dec 15, 2020SVB LeerinkDowngradeOutperformMarket Perform
Dec 14, 2020HC Wainwright & Co.Maintained—Buy
Nov 24, 2020Goldman SachsInitiated—Neutral
Sep 9, 2020SVB LeerinkMaintained—Outperform
May 14, 2020SVB LeerinkMaintained—Outperform